Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma

被引:2
|
作者
Kunimasa, Kei [1 ]
Hirotsu, Yosuke [2 ]
Amemiya, Kenji [2 ]
Honma, Keiichiro [3 ]
Nakamura, Harumi [4 ]
Nishino, Kazumi [1 ]
Omata, Masao [2 ,5 ]
机构
[1] Osaka Int Canc Inst, Dept Thorac Oncol, 3-1-69 Otemae Chuoku, Osaka, Osaka 5418567, Japan
[2] Yamanashi Cent Hosp, Genome Anal Ctr, Kofu, Yamanashi, Japan
[3] Osaka Int Canc Inst, Dept Diagnost Pathol & Cytol, Osaka, Japan
[4] Osaka Int Canc Inst, Lab Genom Pathol, Osaka, Japan
[5] Univ Tokyo, Tokyo, Japan
基金
日本学术振兴会;
关键词
EGFR mutation; intratumor heterogeneity; PD-L1; expression; tumor infiltrating lymphocytes; MUTATIONS; GENOME; CELLS;
D O I
10.1111/1759-7714.15038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we investigated the association between PD-L1 expression in tumor cells and underlying genetic mutations, which was analyzed in detail using laser microdissection and next-generation sequencing analysis. To investigate whether driver mutations are involved in the background of PD-L1 expression, the EGFR major activating mutation was selected as the most frequent driver mutation. Surgical resection specimens were used to extract sufficient amounts of nucleic acids for analysis, and the high tumor proportion score (TPS:100%) and low (TPS: 0%) PD-L1-expressing parts of the tumor were each laser microdissected to examine the association between PD-L1 expression heterogeneity and genetic mutations within the same tumor. The association between PD-L1 heterogeneity and gene mutations within the same tumor was investigated. Analysis showed no association between PD-L1 expression heterogeneity and genetic variants, which were found to be almost identical. However, PD-L1 expression was found to be associated with the number of tumor infiltrating lymphocytes (TILs) present in the tumor, which may be related to whether or not lymphocytes can infiltrate into the tumor depending on the tumor histological type (solid pattern, lepidic pattern, etc.) and other factors.
引用
收藏
页码:2210 / 2215
页数:6
相关论文
共 50 条
  • [1] Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in EGFR-mutated lung adenocarcinoma
    Ito, Atsushi
    Kano, Shu
    Tarukawa, Tomohito
    Suzuki, Yuta
    Sakaguchi, Tadashi
    Ito, Kentaro
    Nishii, Yoichi
    Taguchi, Osamu
    Yasui, Hiroki
    Takao, Motoshi
    Hataji, Osamu
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] Intrinsic Impacts of the Expression of PD-L1 On Postoperative Recurrence in EGFR-Mutated Lung Adenocarcinoma
    Ito, A.
    Kano, S.
    Tarukawa, T.
    Suzuki, Y.
    Sakaguchi, T.
    Ito, K.
    Nishii, Y.
    Taguchi, O.
    Yasui, H.
    Hataji, O.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S552 - S553
  • [3] Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma
    Slomka, Jeremy
    Berthou, Hugo
    Mansuet-Lupo, Audrey
    Blons, Helene
    Fabre, Elizabeth
    Lerner, Ivan
    Rance, Bastien
    Alifano, Marco
    Chapron, Jeanne
    Birsen, Gary
    Gibault, Laure
    Arrondeau, Jennifer
    Leroy, Karen
    Wislez, Marie
    PLOS ONE, 2024, 19 (11):
  • [4] The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
    Hsu, Ping-Chih
    Wang, Chih-Wei
    Kuo, Scott Chih-Hsi
    Lin, Shu-Min
    Lo, Yu-Lun
    Huang, Allen Chung-Cheng
    Chiu, Li-Chung
    Yang, Cheng-Ta
    BIOMEDICINES, 2020, 8 (02)
  • [5] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Lee, S. H.
    Park, M. J.
    Chang, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S572 - S572
  • [6] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Jeon, W.
    Lim, B.
    Han, S.
    Kwack, W.
    Chang, B.
    Choi, H.
    Kim, Y.
    Choi, C.
    Park, M.
    Yoo, J.
    Lee, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [7] Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs
    Lee, Seung Hyeun
    Park, Myung Jae
    Chang, Boksoon
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer
    Xia, W.
    Fu, X. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S431 - S431
  • [9] PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
    Isobe, Kazutoshi
    Kakimoto, Atsushi
    Mikami, Tetuo
    Kaburaki, Kyohei
    Kobayashi, Hiroshi
    Yoshizawa, Takahiro
    Nakano, Yuta
    Makino, Takashi
    Otsuka, Hajime
    Sano, Go
    Sugino, Keishi
    Sakamoto, Susumu
    Takai, Yujiro
    Tochigi, Naobumi
    Iyoda, Akira
    Homma, Sakae
    ONCOLOGY REPORTS, 2018, 40 (01) : 331 - 338
  • [10] Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression
    Kobayashi, Kenichi
    Seike, Masahiro
    Zou, Fenfei
    Noro, Rintaro
    Chiba, Mika
    Ishikawa, Arimi
    Kunugi, Shinobu
    Kubota, Kaoru
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2018, 38 (02) : 753 - 762